This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (63)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Need for Prolongation

Donald D. Bell, MD; John J. Rosental, MD

Arch Surg. 1988;123(9):1169-1172.

Abstract
• As long-term hemodialysis has become well accepted over the last 25 years, so has the need for more exacting and updated techniques for arteriovenous graft construction. The death rate for patients with chronic renal failure undergoing biweekly or triweekly hemodialysis was once generally 10% per year. This pertained to a small, highly selected group of good-risk younger patients. Advancement in dialysis technology and experience has failed to reduce this rate. Essentially, all patients (including ill, elderly, and high-risk patients) are now candidates for long-term hemodialysis. In many cases, prolonged patient survival has added new importance to the extension of arteriovenous graft life. Over the last five years, approximately 1300 arteriovenous graft salvage procedures and new constructions have been performed. Of these, 70% were thrombectomies and revisions for graft salvage. Simple thrombectomy and removal of accumulated neointimal hyperplastic material along the course of the PTFE graft, and especially at the graft-venous anastomotic junction, can often extend graft life another six months to one year or more and permit immediate usage postoperatively. Graft life is even more prolonged with patch angioplasty at venous outflow stenoses or by adding a new segment of PTFE to bypass areas of venous stenosis. Conservation of unused extremities for future arteriovenous graft construction is our goal.

(Arch Surg 1988;123:1169-1172)

Author Affiliations
From the Long Beach Surgical Group, Long Beach, Calif.

Footnotes
Accepted for publication May 9, 1988.

Read before the 59th Annual Meeting of the Pacific Coast Surgical Association, San Francisco, Feb 24, 1988.

Reprint requests to 1045 Atlantic Ave, Suite 1008, Long Beach, CA 90813 (Dr Bell).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Saratin, an Inhibitor of Collagen-Platelet Interaction, Decreases Venous Anastomotic Intimal Hyperplasia in a Canine Dialysis Access Model
Smith et al.
VASC ENDOVASCULAR SURG 2003;37:259-269.
ABSTRACT  

An Evaluation of an Integrative Care Approach for End-Stage Renal Disease Patients
VAN BIESEN et al.
J. Am. Soc. Nephrol. 2000;11:116-125.
ABSTRACT | FULL TEXT  

End-Stage Renal Disease (ESRD) and Vascular Access Grafting: A Critical Review
Szycher
J Biomater Appl 1999;13:297-350.
ABSTRACT